BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, April 27, 2026
Home » Topics » Financings

Financings
Financings RSS Feed RSS

Financings for Sept. 3, 2021

Sep. 3, 2021

Med-tech firms raising money in public or private financings, including: Centaur Diagnostics, Paramit, Seventh Sense Biosystems, Tecan, Yourbio Health.


Read More

Financings for Sept. 3, 2021

Sep. 3, 2021
Biopharmas raising money in public or private financings, including: Locate Bio.
Read More
International currency symbols

Singapore startup Doctor Anywhere banks $88M for telehealth expansion

Sep. 2, 2021
By Catherine Longworth
Health-tech startup Doctor Anywhere Ltd. (DA) has raised $88 million in series C fundraising, as the telehealth sector continues to be attractive for investors. The round is one of the largest private investments ever raised by a Southeast Asian digital health company and was led by growth equity investor Asia Partners. Novo Holdings, Philips, OSK-SBI Venture Partners, EDBI, Square Peg, IHH Healthcare, Kamet Capital and Pavilion Capital also participated.
Read More
Illustration of diabetic foot ulcer, cross section of wound

Rokit wins South Korean approval for diabetic foot ulcers, preps for two IPOs

Sep. 2, 2021
By Gina Lee
Rokit Healthcare Inc. received approval from South Korea’s Ministry of Food and Drug Safety (MFDS) for Dfurege, its artificial organ platform to treat diabetic foot ulcers. “We hope that having a South Korean approval for this platform will be a boost for our planned IPO,” Seok Hwan You, CEO at Rokit, told BioWorld.
Read More

Financings for Sept. 2, 2021

Sep. 2, 2021
Med-tech firms raising money in public or private financings, including: Cloud Dx, DTRT, Laplace Interventional, Sure Retractors.
Read More
Hong Kong stock market illustration

HKEX Biotech Summit 2021: Hong Kong is now financial hub for Chinese biopharmas

Sep. 2, 2021
By Doris Yu
For the last few years, Hong Kong has been the preferred financial hub for many Chinese health care companies to go public and raise money from global investors. “Biotechnology is today the fastest-growing IPO market segment,” said Nicolas Aguzin, CEO of HKEX, during the Hong Kong Exchanges and Clearing Ltd. (HKEX) Biotech Summit 2021.
Read More

Disc Medicine closes $90M series B round to fund two phase II trials

Sep. 2, 2021
By Cormac Sheridan
Disc Medicine Inc. closed a $90 million series B round to move its two lead assets into clinical trials in patients next year. Bitopertin, an oral inhibitor of glycine transporter 1 (GlyT1), is entering a phase II trial in patients with erythropoietic porphyrias (EPPs), a set of rare genetic disorders caused by mutations that disrupt heme synthesis. Disc-0974, an antibody directed against hemojuvelin, will enter a phase II trial in myelofibrosis patients with transfusion-dependent anemia. The molecule, which Disc Medicine in-licensed from North Chicago-based Abbvie Inc., is currently undergoing a phase I trial in healthy volunteers.
Read More

Financings for Sept. 2, 2021

Sep. 2, 2021
Biopharmas raising money in public or private financings, including: Ascendis, Melt.
Read More
DNA illustration

Investors back Dnanudge’s genetic tests with $60M series A investment

Sep. 1, 2021
By Catherine Longworth
Ventura Capital has led a $60 million series A investment round into consumer genetic testing company Dnanudge Ltd. It is the first major fundraising round for the London-based company, which will be used to accelerate deployment of its DNA testing service worldwide. Dnanudge is aiming to tap into the lucrative consumer DNA testing market with Dnaband, a wearable device that stores digital DNA and helps users make healthier choices by personalizing shopping behaviors. The company is also planning a service for personalized skincare shopping.
Read More
Hand holding dollar sign

Onkos Surgical pins $15M in series C funding

Sep. 1, 2021
By Annette Boyle
Onkos Surgical Inc. nabbed an additional $15 million from its existing investors in a series C fundraising round. The Parsippany, N.J.-based company plans to use the new cash to accelerate research and development for its product line which is designed to meet the specialized needs of oncology patients who require orthopedic surgery and the surgeons who work with them.
Read More
Previous 1 2 … 444 445 446 447 448 449 450 451 452 … 667 668 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 24, 2026.
  • Illustration of a tumor

    Detecting the invisible: minimal residual disease at AACR 2026

    BioWorld Science
    Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
  • Boy cupping ear with soundwave graphic

    A free gene therapy? Regeneron’s Otarmeni approved for hearing loss

    BioWorld
    Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
  • Illustration of human face that looks abstract and digital

    AACR 2026: The age of agentic AI in oncology

    BioWorld Science
    New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
  • Chengdu Mfs Pharma synthesizes new compounds for pain

    BioWorld Science
    Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing